Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

455.34 +12.29 (+2.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,362,711
Open 444.74
Bid (Size) 454.00 (1)
Ask (Size) 465.00 (1)
Prev. Close 443.05
Today's Range 443.47 - 456.91
52wk Range 320.01 - 457.66
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... 
Via Talk Markets

Performance

YTD
+10.81%
+10.81%
1 Month
+13.62%
+13.62%
3 Month
+5.87%
+5.87%
6 Month
+28.98%
+28.98%
1 Year
+36.89%
+36.89%

More News

Read More
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
Via Investor's Business Daily
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Via The Motley Fool
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
Via Chartmill
2 Biotech Stocks to Buy in May
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Via Benzinga
Got $500? 3 Pharma Stocks to Buy and Hold Forever
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
SLB, First Solar And 2 Other Stocks Insiders Are Selling
Via Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Via Benzinga
Should you consider NASDAQ:VRTX for quality investing?
Via Chartmill
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
Via InvestorPlace
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Via Benzinga
Exposures COVID-19
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
3 Cheap Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Exposures Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.